Imugene Limited

Imugene (ASX:IMU) share placement to raise $24.6 million

02/12/2019 15:01:00

Key points:   - Oversubscribed placement commitments to sophisticated and professional investors to raise $24.6 million - Capital raising fully funds the Company’s clinical programs incl…

Imugene Limited (ASX:IMU) - trading halt

28/11/2019 09:32:00

The securities of Imugene Limited ('IMU') will be placed in trading halt at the request of IMU, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain…

US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy

23/10/2019 12:38:00

Sydney, Australia, 23 October 2019: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Profe…

Market Reports / by Ortenzia Borre - 26 days ago

Imugene Limited (ASX:IMU) completes OV acquisition: Aus shares 0.6% lower at noon

18 Nov 2019 - Australian share market dipped on open despite ‘constructive discussions’ regarding the phase-one China and US trade deal between negotiators. Imugene Limited (ASX:IM…

Market Reports / by Jessica Amir - 5 months ago

RBA cut rates to historical low, banks under pressure: Aus shares close 0.1% higher

02 Jul 2019 - Australian share market falls after RBA cut rates as expected to 1%, but the ASX200 claws back into positive territory, rising for the 2nd session. Financials lost ov…

Company Presentations / by - 6 months ago

Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vac…

Interviews / by Anna Napoli - 6 months ago

Imugene (ASX:IMU) targeting gastric cancer

27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong discusses trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vacci…

Company News / by Rachael Jones - 7 months ago

Imugene’s HER-Vaxx to be presented at US oncology meeting

29 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) will present data from its Phase Ib study of its HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Onc…

Company News / by Rachael Jones - 7 months ago

Imugene appoints Dr Lesley Russell to the board

23 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) has appointed Dr Lesley Russell as a Non-Executive Director, a leading global pharmaceutical executive.

Company News / by Rachael Jones - 8 months ago

Imugene presents new data on cancer vaccines AACR

02 Apr 2019 - Biotech company Imugene (ASX:IMU) presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research Annual Meeting…

Market Reports / by Katrina Bullock - 8 months ago

Linius Technologies displays new blockchain tech: Aus shares 0.9% higher at noon

22 Mar 2019 - The S&P/ASX 200 opened higher this morning following strong leads from Wall Street where US equities reached a five-month high. The market continues to rally into the…

Company News / by Rachael Jones - 9 months ago

Imugene doses first patient in Moldova with cancer vaccine

14 Mar 2019 - Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.

Company News / by Anna Napoli - 11 months ago

Imugene appoints distinguished scientist to SAB

07 Jan 2019 - Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.

Company Presentations / by - A year ago

Imugene (ASX:IMU) Presentation, FNN Investor Event, October 2018, Sydney

26 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell…

Interviews / by Rachael Jones - A year ago

Imugene (ASX:IMU) targeting gastric cancer

29 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong talks trial progress with the company's lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines …

Market Reports / by Rachael Jones - A year ago

Healthcare sector stays in the green: ASX closes 0.6% lower

01 Oct 2018 - It's been a quiet day on the markets with the ASX closing lower. New Zealand software company Xero did well today, Nufarm shares were down. The Canadian dollar and Me…

Company News / by Anna Napoli - A year ago

Imugene appoints leading cancer researcher to board

01 Oct 2018 - Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.

Company News / by Rachael Jones - A year ago

Imugene starts manufacture of KEY-Vaxx for trials

21 Sep 2018 - Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx.

Company News / by Anna Napoli - A year ago

Imugene completes recruitment for Phase 1b clinical trial of HER-Vaxx

11 Sep 2018 - Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recrui…

Market Reports / by Jessica Amir - A year ago

Out of puff on Friday: Aus shares close 0.9% higher on week

08 Jun 2018 - Market Wrap. ASX20, ASX50, ASX100 and ASX200 reshuffled with Afterpay Touch (ASX:APT) & Kidman Resources (ASX:KDR) in ASX200. MMJ PhyoTech (ASX:MMJ) pleased Canada cl…

Interviews / by Rachael Jones - A year ago

Imugene (ASX:IMU) 1H18 results & outlook

09 March 2018 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks 1H18 and outlook, including progress with the company's lead HER-Vaxx cancer vaccine.

Company News / by Kathy Skantzos - 2 years ago

Imugene raises $8.7 million for clinical trial

23 Nov 2017 - Immune-oncology company Imugene (ASX:IMU) raises $8.7 million through a $6.7 million institutional placement and a $2 million fully underwritten entitlement offer.

Company Presentations / by - 2 years ago

Imugene (ASX:IMU) Presentation, FNN Small Cap Investor Event, October 2017, Sydney

12 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong presents at the FNN Small Cap Investor Event, October 2017, Sydney.

Interviews / by Jessica Amir - 2 years ago

Imugene (ASX:IMU) talks Phase 1 & 2 cancer trials

11 Oct 2017 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks cancer trials for the company's lead drug candidate, HER-Vaxx, strategy and outlook.

Market Reports / by - 3 years ago

Market Wrap: Aus shares close 0.48% lower

04 Jan 2016 - Aus shares close 0.48% lower. Amaysim Australia Limited (ASX:AYS) acquires mobile virtual network operator Vaya.

Company News / by - 4 years ago

Imugene Vaxx shows dramatic improvement

20 Apr 2015 - Imugene Limited (ASX:IMU) says leading cancer vaccination is showing a dramatic ten-fold increase in antibodies and has met an additional milestone.

Market Reports / by - 5 years ago

Midday: ASX follows global selloff

08 Oct 2014 - ASX follows global selloff. BC Iron Limited (ASX:BCI) increases its relevant interest in Iron Ore Holdings to 90.37%.